Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential

被引：7
|
作者：
Wilson, Brooke E. [1 ,2 ]
Shen, Qiang [3 ]
Cescon, David W. [4 ,5 ]
Reedijk, Michael [4 ,5 ,6 ]
机构：
[1] Queens Univ, Dept Oncol, Kingston, ON, Canada
[2] Queens Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Hlth Network, Dept Surg Oncol, Toronto, ON, Canada
来源：
FRONTIERS IN GENETICS | 2023年 / 14卷
关键词：
triple negative breast cancer; IL1beta; immunotherapy; tumor microenvironment; inflammasome; TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; PHASE-III; INFLAMMATION; MACROPHAGES; MECHANISM; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; CANAKINUMAB;
D O I：
10.3389/fgene.2023.1086163
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Triple negative breast cancer (TNBC) has poor prognosis when compared to other breast cancer subtypes. Despite pre-clinical data supporting an immune targeted approach for TNBCs, immunotherapy has failed to demonstrate the impressive responses seen in other solid tumor malignancies. Additional strategies to modify the tumor immune microenvironment and potentiate response to immunotherapy are needed. In this review, we summarise phase III data supporting the use of immunotherapy for TNBC. We discuss the role of IL-1 beta in tumorigenesis and summarize pre-clinical data supporting IL-1 beta inhibition as a potential therapeutic strategy in TNBC. Finally, we present current trials evaluating IL-1 beta in breast cancer and other solid tumor malignancies and discuss future studies that may provide a strong scientific rationale for the combination of IL-1 beta and immunotherapy in the neoadjuvant and metastatic setting for people with TNBC.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Expression of EGFR, IL-1, amphiregulin, and NFκB in triple negative breast cancer, and their correlation with histologic findings
    Vakil, H.
    Aldeen, B. Sharaf
    Safadi, A.
    Nassar, H.
    LABORATORY INVESTIGATION, 2008, 88 : 57A - 57A
  • [42] Celastrol attenuates the inflammatory response by inhibiting IL-1β expression in triple-negative breast cancer cells
    You, Daeun
    Jeong, Yisun
    Yoon, Sun Young
    Kim, Sung A.
    Kim, Seok Won
    Nam, Seok Jin
    Lee, Jeong Eon
    Kim, Sangmin
    ONCOLOGY REPORTS, 2021, 45 (06)
  • [43] Expression of EGFR, IL-1, amphiregulin, and NFκB in triple negative breast cancer, and their correlation with histologic findings
    Vakil, H.
    Aldeen, B. Sharaf
    Safadi, A.
    Nassar, H.
    MODERN PATHOLOGY, 2008, 21 : 57A - 57A
  • [44] Therapeutic targets in triple negative breast cancer
    O'Toole, Sandra A.
    Beith, Jane M.
    Millar, Ewan K. A.
    West, Richard
    McLean, Anna
    Cazet, Aurelie
    Swarbrick, Alexander
    Oakes, Samantha R.
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (06) : 530 - 542
  • [45] SCD-1 blockade sensitizes triple negative breast cancer to immune checkpoint inhibition.
    Vivekanandhan, Sneha
    Trynda, Justyna
    Marlow, Laura A.
    Shreeder, Barath
    Miller, James L.
    Kase, Adam M.
    Tan, Winston
    Knutson, Keith L.
    Copland, John A.
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (vol 40, pg 189, 2021)
    Kung, Che-Pei
    Cottrell, Kyle A.
    Ryu, Sua
    Bramel, Emily R.
    Kladney, Raleigh D.
    Bao, Emily A.
    Freeman, Eric C.
    Sabloak, Thwisha
    Maggi, Leonard, Jr.
    Weber, Jason D.
    ONCOGENE, 2021, 40 (11) : 2147 - 2147
  • [47] Identification of lncRNAs as potential novel therapeutic targets in triple negative breast cancer
    O'Malley, Megan
    Rana, Zohaib
    Sarkar, Debina
    Chia, Jolyn
    Diermeier, Sarah
    CANCER RESEARCH, 2023, 83 (07)
  • [48] On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer
    Boudghene-Stambouli, Fadia
    Soulez, Mathilde
    Ronkina, Natalia
    Doerrie, Anneke
    Kotlyarov, Alexey
    Seternes, Ole-Morten
    Gaestel, Matthias
    Meloche, Sylvain
    CANCERS, 2023, 15 (01)
  • [49] Therapeutic potential of ERK5 targeting in triple negative breast cancer
    Jesus Ortiz-Ruiz, Maria
    Alvarez-Fernandez, Stela
    Parrott, Tracy
    Zaknoen, Sara
    Burrows, Francis J.
    Ocana, Alberto
    Pandiella, Atanasio
    Esparis-Ogando, Azucena
    ONCOTARGET, 2014, 5 (22) : 11308 - 11318
  • [50] The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer
    Kaur, Sukhmandeep
    Mendonca, Patricia
    Soliman, Karam F. A.
    NUTRIENTS, 2024, 16 (15)
12345